Drug intelligence / Profile preview

PD1-T cells

Development stage: Phase 3
Modality: Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PD1-T cells are a type of adoptive cell immunotherapy, specifically described as PD-1 blockade-activated DC-CIK (cytokine-induced killer) cells. This cell therapy is being investigated as a first-line treatment for previously untreated metastatic colorectal cancer (mCRC) in combination with XELOX (capecitabine plus oxaliplatin) and bevacizumab. The therapy aims to enhance the anti-tumor immune response by modulating the PD-1 pathway, leading to significant clinical improvements in progression-free survival and overall survival with good tolerability.

Other names: PD-1 blockade-activated DC-CIK (PD1-T) cells

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PD1-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD1-T cells.

Explore the full profile